Literature DB >> 16897587

Cellular immune response of patients with chromoblastomycosis undergoing antifungal therapy.

Viviane Mazo Fávero Gimenes1, Paulo Ricardo Criado, José Eduardo Costa Martins, Sandro Rogério Almeida.   

Abstract

One of the most characteristic features of the chromoblastomycosis is its unresponsiveness to treatment. In order to analyzed whether during therapy could be observed a change of cellular immune response pattern, we evaluated the production of IL-10, TNF-alpha and IFN-gamma, as well as proliferation of peripheral blood mononuclear cell (PBMC) from patients in different periods of chemotherapy treatment. Our results showed that after 6 months of treatment cells from patients proliferated to fungal antigens and produced a significant level of IFN-gamma. However, after 1 year of treatment a low proliferation of T cells and production of IFN-gamma accompanied by an increase of IL-10 were observed when compared with 6 months of treatment.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16897587     DOI： 10.1007/s11046-006-0041-x

Source DB:  PubMed          Journal:  Mycopathologia        ISSN： 0301-486X            Impact factor:   3.785


  23 in total

1.  Elevated serum concentrations of interleukin-10 in nonneutropenic patients with invasive aspergillosis.

Authors:  E Roilides; T Sein; M Roden; R L Schaufele; T J Walsh
Journal:  J Infect Dis       Date:  2001-02-01       Impact factor: 5.226

Review 2.  Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy.

Authors:  K V Clemons; D A Stevens
Journal:  Semin Respir Infect       Date:  2001-03

3.  Chromomycosis: a therapeutic challenge.

Authors:  L G Castro
Journal:  Clin Infect Dis       Date:  1992-09       Impact factor: 9.079

4.  Immunity to fungi: editorial overview.

Authors:  L Romani; S H Kaufmann
Journal:  Res Immunol       Date:  1998 May-Jun

5.  Chromomycosis: a clinical and mycologic study of thirty-five cases observed in the hinterland of Rio Grande do Sul, Brazil.

Authors:  A T Londero; C D Ramos
Journal:  Am J Trop Med Hyg       Date:  1976-01       Impact factor: 2.345

6.  A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis.

Authors:  D Borelli
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

7.  Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi.

Authors:  F Queiroz-Telles; K S Purim; J N Fillus; G F Bordignon; R P Lameira; J Van Cutsem; G Cauwenbergh
Journal:  Int J Dermatol       Date:  1992-11       Impact factor: 2.736

8.  Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology.

Authors:  M R McGinnis
Journal:  J Am Acad Dermatol       Date:  1983-01       Impact factor: 11.527

9.  Increased serum concentrations of interleukin-10 in patients with hepatosplenic candidiasis.

Authors:  E Roilides; T Sein; R Schaufele; S J Chanock; T J Walsh
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

10.  Modulation of CD28 and CD86 expression in patients with paracoccidioidomycosis in different periods of treatment.

Authors:  A Bozzi; B S Reis; F L S Prado; E P Pedroso; M F Leite; A M Goes
Journal:  Scand J Immunol       Date:  2004-11       Impact factor: 3.487
View more
  7 in total

Review 1.  Black yeasts and their filamentous relatives: principles of pathogenesis and host defense.

Authors:  Seyedmojtaba Seyedmousavi; Mihai G Netea; Johan W Mouton; Willem J G Melchers; Paul E Verweij; G Sybren de Hoog
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  The cell wall fraction from Fonsecaea pedrosoi stimulates production of different profiles of cytokines and nitric oxide by murine peritoneal cells in vitro.

Authors:  Yanna Karla de Medeiros Nóbrega; Viviane Furlan Lozano; Tarciane Silva de Araújo; Daniel Diniz de Carvalho; Anamélia Lorenzetti Bocca
Journal:  Mycopathologia       Date:  2010-03-30       Impact factor: 2.574

Review 3.  Chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Sybren de Hoog; Daniel Wagner C L Santos; Claudio Guedes Salgado; Vania Aparecida Vicente; Alexandro Bonifaz; Emmanuel Roilides; Liyan Xi; Conceição de Maria Pedrozo E Silva Azevedo; Moises Batista da Silva; Zoe Dorothea Pana; Arnaldo Lopes Colombo; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

4.  DNA-hsp65 vaccine as therapeutic strategy to treat experimental chromoblastomycosis caused by Fonsecaea pedrosoi.

Authors:  Isaque Medeiros Siqueira; Alice Melo Ribeiro; Yanna Karla de Medeiros Nóbrega; Karina Smidt Simon; Ana Camila Oliveira Souza; Márcio Souza Jerônimo; Florêncio Figueiredo Cavalcante Neto; Célio Lopes Silva; Maria Sueli Soares Felipe; Anamélia Lorenzetti Bocca
Journal:  Mycopathologia       Date:  2012-11-22       Impact factor: 2.574

Review 5.  Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis.

Authors:  Luiz Felipe Domingues Passero; Italo Novais Cavallone; Walter Belda
Journal:  J Immunol Res       Date:  2021-11-01       Impact factor: 4.818

6.  Transformation of Fonsecaea pedrosoi into sclerotic cells links to the refractoriness of experimental chromoblastomycosis in BALB/c mice via a mechanism involving a chitin-induced impairment of IFN-γ production.

Authors:  Bilin Dong; Zhongsheng Tong; Ruoyu Li; Sharon C-A Chen; Weihuang Liu; Wei Liu; Yao Chen; Xu Zhang; Yiqun Duan; Dongsheng Li; Liuqing Chen
Journal:  PLoS Negl Trop Dis       Date:  2018-02-26

7.  Early immune response against Fonsecaea pedrosoi requires Dectin-2-mediated Th17 activity, whereas Th1 response, aided by Treg cells, is crucial for fungal clearance in later stage of experimental chromoblastomycosis.

Authors:  Isaque Medeiros Siqueira; Marcel Wüthrich; Mengyi Li; Huafeng Wang; Lucas de Oliveira Las-Casas; Raffael Júnio Araújo de Castro; Bruce Klein; Anamelia Lorenzetti Bocca
Journal:  PLoS Negl Trop Dis       Date:  2020-06-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.